Asieh Heirani-Tabasi

Asieh Heirani-Tabasi

Auto-generated profile, based on publicly available information

Asieh Heirani-Tabasi

Research Center for Advanced Technologies in Cardiovascular Medicine, Cardiovascular Research Institute, Tehran Heart Center, Tehran University of Medical Sciences, Tehran, Iran

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2021 in Biosensors
Verified
Journal Article
Open access
PDF file
HNHojjatollah Nazari
Hojjatollah Nazari
AHAsieh Heirani-Tabasi
Asieh Heirani-Tabasi
SGSadegh Ghorbani
Sadegh Ghorbani
HEHossein Eyni
Hossein Eyni
Sajad Razavi BazazSajad Razavi Bazaz
Sajad Razavi Bazaz
Majid Ebrahimi WarkianiMajid Ebrahimi Warkiani
Majid Ebrahimi Warkiani
Microfluidics is a promising approach for the facile and large-scale fabrication of monodispersed droplets for various applications in biomedicine. This technology has demonstrated great potential to address the limitations of regenerative medicine. Microfluidics provides safe, accurate, reliable, and cost-effective methods for encapsulating different stem cells, gametes, biomaterials, biomolecules, reagents, genes, and nanoparticles inside picoliter-sized droplets or droplet-derived microgels for different applications. Moreover, microenvironments made using such droplets can mimic niches of stem cells for cell therapy purposes, simulate native extracellular matrix (ECM) for tissue engineering applications, and remove challenges in cell encapsulation and three-dimensional (3D) culture methods. The fabrication of droplets using microfluidics also provides controllable microenvironments for manipulating gametes, fertilization, and embryo cultures for reproductive medicine. This review focuses on the relevant studies, and the latest progress in applying droplets in stem cell therapy, tissue engineering, reproductive biology, and gene therapy are separately evaluated. In the end, we discuss the challenges ahead in the field of microfluidics-based droplets for advanced regenerative medicine.

6 September 2024 in Diseases of the Colon & Rectum
Verified
Journal Article
Closed access
AHalireza hadizadeh
alireza hadizadeh
RAReza Akbari Asbagh
Reza Akbari Asbagh
AHAsieh Heirani-Tabasi
Asieh Heirani-Tabasi
MSMasoud Soleimani
Masoud Soleimani
PGParastou Gorovanchi
Parastou Gorovanchi
STSeyed mohsen Ahmadi Tafti
Seyed mohsen Ahmadi Tafti
BACKGROUND: Crohn’s disease perianal fistulas are often resistant to standard anti–tumor necrosis factor-α therapies. Mesenchymal stem cell–derived exosomes are extracellular vesicles with highly potent anti-inflammatory effects, and the previous phase of this study demonstrated their safety in the treatment of refractory perianal fistulas. OBJECTIVE: To evaluate the efficacy of mesenchymal stem cell–derived exosomes for the treatment of refractory perianal fistulas. DESIGN: Nonrandomized, nonblinded single-center phase II clinical trial. SETTINGS: Tertiary university hospital. PATIENTS: Twenty-three patients were enrolled, 20 of whom completed the study. Refractory perianal fistula was defined as resistance to at least 1 course of treatment with anti–tumor necrosis factor-α therapy. INTERVENTIONS: After clinical assessment and MRI, the patients received general anesthesia, and 5 mL of exosome solution was injected directly into the fistula tracts. The injections were repeated 3 times at 2-month intervals, and patients were followed monthly for 6 months after the last injection. Tissue samples from the tracts were obtained before each injection and subjected to immunohistopathological assessment. MRI data were obtained before and 6 months after the last injection. MAIN OUTCOME MEASURES: The primary outcome of this study was fistula tract closure on clinical examination and MRI. The secondary outcome was an improvement in the discharge from the tracts. RESULTS: Fistula tracts were fully closed in 12 patients (60%). Four patients showed clinical improvement, with some tracts remaining open, and 4 patients were completely resistant to treatment. A total of 43 fistula tracts were treated during the trial, 30 of which (69.7%) showed complete closure. Histopathological analysis revealed substantial reductions in local inflammation and signs of enhanced tissue regeneration. Immunohistochemical analysis of CD68, CD20, and CD31 reaffirmed these results. CONCLUSIONS: Mesenchymal stem cell–derived exosomes are safe and effective for treating refractory perianal fistulas in patients with Crohn’s disease. See Video Abstract. ADMINISTRACIÓN LOCALIZADA DE EXOSOMAS DERIVADOS DE CÉLULAS MADRE MESENQUIMALES PARA EL TRATAMIENTO DE LA FÍSTULA PERIANAL REFRACTARIA EN PACIENTES CON ENFERMEDAD DE CROHN: ENSAYO CLÍNICO DE FASE II: ANTECEDENTES: Las fístulas perianales de la enfermedad de Crohn a menudo son resistentes a las terapias anti-TNF-α estándares. Los exosomas derivados de células madre mesenquimales (MSC) son vesículas extracelulares que tienen efectos antiinflamatorios muy potentes, y la fase anterior de este estudio demostró su seguridad en el tratamiento de fístulas perianales refractarias. OBJETIVO: Evaluar la eficacia de los exosomas derivados de MSC para el tratamiento de fístulas perianales refractarias. DISEÑO: Ensayo clínico de fase II, no aleatorizado y no ciego, unicéntrico. LUGARES: Hospital universitario terciario. PACIENTES: Se inscribieron veintitrés pacientes, 20 de los cuales completaron el estudio. La fístula perianal refractaria se definió como la resistencia a al menos un ciclo de tratamiento con terapia anti-TNF-α. INTERVENCIONES: Después de la evaluación clínica y la resonancia magnética, los pacientes fueron sometidos a anestesia general y se inyectaron 5 ml de solución de exosoma directamente en los trayectos de la fístula. Las inyecciones se repitieron tres veces a intervalos de 2 meses y los pacientes fueron seguidos mensualmente durante 6 meses después de la última inyección. Se obtuvieron muestras de tejido de los tractos antes de cada inyección y se sometieron a evaluación inmunohistopatológica. Los datos de imágenes de resonancia magnética se obtuvieron antes y seis meses después de la última inyección. PRINCIPALES MEDIDAS DE RESULTADO: El resultado primario de este estudio fue el cierre del trayecto de la fístula en el examen clínico y la imagen de resonancia magnética. El resultado secundario fue una mejora en la descarga de los tractos. RESULTADOS: Los trayectos de la fístula se cerraron completamente en 12 (60%) de los pacientes. Cuatro pacientes mostraron mejoría clínica, algunos tractos permanecieron abiertos y cuatro pacientes fueron completamente resistentes al tratamiento. Durante el ensayo se trataron un total de 43 trayectos fistulosos, 30 (69,7%) de los cuales mostraron un cierre completo. El análisis histopatológico reveló reducciones sustanciales en la inflamación local y signos de una mayor regeneración tisular. El análisis inmunohistoquímico del grupo de diferenciación 68, 20 y 31 reafirmó estos resultados. CONCLUSIONES: Los exosomas derivados de MSC son seguros y eficaces para el tratamiento de fístulas perianales refractarias en pacientes con enfermedad de Crohn. (Traducción—Dr. Aurian Garcia Gonzalez)

22 July 2021 in Inflammatory Bowel Diseases
Verified
Journal Article
Closed access
HNHojjatollah Nazari
Hojjatollah Nazari
VNVahid Yaghoubi Naei
Vahid Yaghoubi Naei
ATAsieh Heirani Tabasi
Asieh Heirani Tabasi
ABAbolfazl Badripour
Abolfazl Badripour
RAReza Akbari Asbagh
Reza Akbari Asbagh
STSeyed Mohsen Ahmadi Tafti
Seyed Mohsen Ahmadi Tafti
Regenerative medicine is an emerging therapeutic method that aims to reconstruct tissues and organs. This advanced therapeutic approach has demonstrated great potential in addressing the limitations of medical and surgical procedures for treating perineal fistula in patients with Crohn’s disease. Recent developments in stem cell technology have led to a massive good manufacturing practices (GMPs) production of various stem cells, including mesenchymal and embryonic cells, along with induction of pluripotent stem cells to repair damaged tissues in the fistula. The recent advances in separation and purification of exosomes, as biologic nanovesicles carrying anti-inflammatory and regenerative agents, have made them powerful tools to treat this inflammatory disease. Further, tremendous advances in nanotechnology, biomaterials, and scaffold fabrication methods enable tissue engineering methods to synthesize tissue-like structures to assist surgical techniques. This review focuses on advanced regenerative-based methods including stem cell therapy, exosome therapy, and tissue engineering used in the treatment of perianal fistula. Relevant in vitro and in vivo studies and the latest innovations in implementation of regenerative medicine for this disease are also separately reviewed. Additionally, current challenges regarding implementation of g stem cells, exosomes, and tissue engineering methods for bridging the gaps between laboratory findings and clinic application will be discussed.

19 August 2020 in Cell and Tissue Banking
Verified
Journal Article
Closed access
PDF file
AHAsieh Heirani-Tabasi
Asieh Heirani-Tabasi
MMMahdi Mirahmadi
Mahdi Mirahmadi
MMMohammad Amir Mishan
Mohammad Amir Mishan
HNHojjat Naderi-Meshkin
Hojjat Naderi-Meshkin
STShirin Toosi
Shirin Toosi
ABAhmad Reza Bahrami
Ahmad Reza Bahrami

16 June 2022
Verified
Preprint
Open access
PDF file
HNHojjatollah Nazari
Hojjatollah Nazari
AHAsieh Heirani-Tabasi
Asieh Heirani-Tabasi
MSMasoud Soleimani
Masoud Soleimani
AHalireza hadizadeh
alireza hadizadeh
RAReza Akbari Asbagh
Reza Akbari Asbagh
STSeyed Mohsen Ahmadi Tafti
Seyed Mohsen Ahmadi Tafti
Background and objectives: Exosomes therapy is a promising technique that can decrease the concern related to the fate of transplanted stem cells to the fistula location. The unique properties of mesenchymal stem cells (MSCs)-derived exosomes can improve fistula healing because of their high ability to regulate and modify immune responses. This project aims to examine the safety and efficacy of implementing MSCs-exosomes in treating refractory fistulas in inflammatory bowel disease (IBD) patients. Methods : The exosomes were isolated from umbilical cord-derived MSCs and characterized using flow cytometry, western blotting, and transmittance electron microscope (TEM). Five patients (three men and two women) with refractory perianal Crohn's disease with an average age of 35.4 years old were included. The patients did not match the exclusion criteria, and the presence of refractory fistulas was the main inclusion criteria. These patients have their exosomes injections in the operation room. The therapy responses of patients were assessed using physical examination, face-to-face interviews, computerized tomography (CT) scan, and magnetic resonance imaging (MRI) six months later. Result : The Following injection, patients reported a 70% improvement on average. Two patients claimed complete healing after exosome injections, while one patient reported no improvement and active discharge from the fistula site. In addition, five patients reported no adverse effects, both systemic or on the injection site. Conclusion : Injection of exosomes extracted from MSCs shows total safety and a satisfactory therapeutic impact, as shown in this and other research, and could play a significant role in the treatment of gastrointestinal fistulas in the future.

2 January 2016 in Cell Therapy and Regenerative Medicine Journal
Verified
Journal Article
Open access
STShirin Hamedakbari Toosi
Shirin Hamedakbari Toosi
JBJavad Behravan
Javad Behravan
AHAsieh Heirani-Tabasi
Asieh Heirani-Tabasi